ClinicalTrials.gg
CompletedNCT04549155NetTMSUpdated Oct 27, 2026Results posted

Network-guided TMS in Early Alzheimer's Disease

An interventional study of Transcranial Magnetic Stimulation in Mild Cognitive Impairment, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 60 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

Updated Oct 27, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
60 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Cognitive Dysfunction by Duke University — 4 open to participants now, 4 under way, none of them phase 3. Cognitive Dysfunction · Duke University.

Enrollment
8th of 14
37 · median 48
Started
2022
with 2 others
No phase
11 of 20
1 open now
Registered
16th of 20
by date

Among the 20 studies in Cognitive Dysfunction by Duke University, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 11 with no phase, and was the 16th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

4 of the 20 studies in Cognitive Dysfunction by Duke University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 82 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cognitive Dysfunction by Duke University, or all of them as a file.
02

Study summary

The proposed research will test a novel network-based neurostimulation approach using MRI-derived measures of brain connectivity to establish target sites for neurostimulation and test for the enhancement of memory function beyond a sham stimulation condition. This will be tested in cohort of MCI adults using network-based transcranial magnetic stimulation (TMS) to assess for behavioral improvement due to the controlled intervention. This study will provide important evidence towards the efficacy of neuromodulatory treatments for memory decline and will accelerate the discovery of potent non-invasive treatments to remediate cognitive decline in cognitively impaired older adults.

Read the detailed description

Dementia due to Alzheimer's disease (AD) is a leading public health concern in the US with tremendous care costs and no effective pharmacotherapy despite multiple clinical trials. Numerous studies have shown mild cognitive impairment (MCI) to be a precursor to AD and potentially amenable to nonpharmacological intervention. Transcranial magnetic stimulation (TMS) is a promising non-invasive therapeutic approach that has been shown to increase brain plasticity and enhance cognitive functions that are impaired across the AD spectrum. Yet, while TMS has shown benefits in normative populations, there is still a need to show efficacy in AD-related populations.

Most previous neurostimulation research on AD and MCI has focused on effects of stimulation at one brain region, however the cognitive processes underlying successful memory are mediated by a complex whole-brain network. Neurostimulation affects multiple sites within a cortical network, but these more global effects have not been used as targets for stimulation because of limited knowledge about what influence of a single site on more widespread cortical changes. The novelty of the current proposal is that the investigators use information about the network control structure of the affected brain areas by considering the influence of neuromodulation on global changes in brain state or connectivity and the underlying vascular changes mediating long-term consequences for behavior. This network-based TMS is informed by functional connectivity and neurovascular as mediators of the behavioral response as a means to specifically tailor the TMS treatment to the neuropathology of each MCI patient, thus individualizing the treatment to achieve better therapeutic effects.

To address this problem, the investigators will use multimodal neuroimaging and network modeling during an episodic memory task to demonstrate how focal neurostimulation evokes changes in neural function and behavior in MCI. These goals will be addressed in two specific aims. First, the investigators will use network-based TMS to optimize the activation of a memory success network (MSN) in a group of MCI patients, targeting a TMS site that focused on the controllability of a stimulation site to provide the maximum benefit to memory performance. Second, the study team will assess longitudinal change in structural and neurovascular factors affecting the efficacy of individualized network-based TMS across multiple sessions of concurrent TMS-fMRI. By creating a multimodal model of these neurovascular deficits related to MCI, the investigators will systematically adjust network-based TMS to demonstrate how the MCI brain might compensate for these neural deficits. The proposed work will be the first of its kind to estimate the utility of network controllability as a TMS target for memory enhancement in AD-related syndromes, and the first to assess the short-term neuroplastic effects of neuromodulation in such rich detail. The knowledge gained by this project may therefore lead to novel and innovative biometrics for gauging pharmacological and nonpharmacological treatment response or for targeted and enriched clinical trials in AD and related disorders.

03

Conditions studied

  • Mild Cognitive Impairment
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
60 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elderly: age between 60-82
  • English speaking
  • Willing to provide consent
  • Signed HIPAA authorization
  • Use of effective method of for women of childbearing capacity
  • Clinical Consensus for MCI

Exclusion criteria

Exclusion Criteria:

  • History of any Axis I disorder
  • Current or past history of substance abuse or dependence (excluding nicotine)
  • Women who are pregnant or breast feeding
  • Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes), cardiac pacemakers, or vagus Nerve stimulation device
  • Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma with loss of consciousness for ≥ 30 minutes.
  • Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; fainting, cerebral aneurysm,
  • Dementia, Hungtington chorea; Multiple Sclerosis.
  • Current use of medications known to lower the seizure threshold and/or affect working memory
  • Current or past history of substance abuse or dependence (excluding nicotine)
  • Women who are pregnant or breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Network-guided TMS

    The study comprises one arm of five sessions. In Day 1 (\~1.5 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (\~1 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. In Days 3-5 (each comprising a \~2.5 hr session) a few days later participants will undergo combined TMS-fMRI sessions. In the scanner, participants complete four fMRI runs: 2 runs using either a network-based or standard target location, counterbalanced across participants. Active and Sham TMS trials are intermixed within each run.

    Device: Transcranial Magnetic Stimulation

Interventions

  • DeviceTranscranial Magnetic Stimulation

    Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.

    Also known as: TMS, rTMS

06

What researchers measure

Primary outcomes

  1. Episodic Memory Task Performance

    The primary outcome measure is the difference in memory accuracy between TMS conditions (active vs. sham) on an episodic memory task. Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. During the Retrieval phase (post-scan), participants perform a recognition memory task including a mix of old objects and new objects, and memory is then subsequently assessed as a function of TMS condition. Reported as a hit rate, calculated by dividing the number of correct responses by the number of presented tasks.

    Time frame: Baseline + Follow-up session, at day 3

  2. Change in Representational Strength of Episodic Memories

    The primary outcome measure is the difference in Representational Strength between TMS conditions (active vs. sham) during the episodic encoding task, at the site of TMS stimulation (Lateral Parietal Cortex). Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. Representational strength reflects the degree to which participants use semantic or perceptual information during encoding. Representational strength is calculated by comparing the similarity in activation patterns in a given brain region with the similarity in model estimates (semantic model: overlap of semantic features; perceptual model: overlap of perceptual features. As such, this measure reflects a Pearson's correlation (between -1 and 1) between brain and model similarity measures.

    Time frame: Baseline + Follow-up session, at day 3

07

Results

Posted Oct 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneNetwork-guided TMSSham TMS
Started2017
Completed1217
Not completed80
Withdrew: Adverse event10
Withdrew: Withdrawal by subject40
Withdrew: Withdrawal by pi30

Outcome measures

PrimaryEpisodic Memory Task Performance

The primary outcome measure is the difference in memory accuracy between TMS conditions (active vs. sham) on an episodic memory task. Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. During the Retrieval phase (post-scan), participants perform a recognition memory task including a mix of old objects and new objects, and memory is then subsequently assessed as a function of TMS condition. Reported as a hit rate, calculated by dividing the number of correct responses by the number of presented tasks.

Time frame:
Baseline + Follow-up session, at day 3
Reported as:
Mean · proportion of correct responses
Episodic Memory Task Performance
proportion of correct responsesNetwork-guided TMSSham TMS
Baseline0.64 ± 0.120.66 ± 0.16
Follow-up Session0.78 ± 0.120.69 ± 0.08
Statistical analysis
  • Network-guided TMS vs Sham TMS · Regression, Linear · p = 0.0049 (The a priori threshold for statistical significance was alpha = 0.05.)
PrimaryChange in Representational Strength of Episodic Memories

The primary outcome measure is the difference in Representational Strength between TMS conditions (active vs. sham) during the episodic encoding task, at the site of TMS stimulation (Lateral Parietal Cortex). Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. Representational strength reflects the degree to which participants use semantic or perceptual information during encoding. Representational strength is calculated by comparing the similarity in activation patterns in a given brain region with the similarity in model estimates (semantic model: overlap of semantic features; perceptual model: overlap of perceptual features. As such, this measure reflects a Pearson's correlation (between -1 and 1) between brain and model similarity measures.

Time frame:
Baseline + Follow-up session, at day 3
Reported as:
Mean · Correlation coefficient
Change in Representational Strength of Episodic Memories
Correlation coefficientNetwork-guided TMSSham TMS
Baseline0.018 ± 0.040.013 ± 0.04
Follow-up Sessions0.029 ± 0.040.011 ± 0.04
Statistical analysis
  • Network-guided TMS vs Sham TMS · Regression, Linear · p = 0.034 (The a priori threshold for statistical significance was alpha = 0.05.)A Benjamini-Hochberg (BH) correction for multiple comparisons was applied.

Adverse events

Collected over Up to 72 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Network-guided TMS0/20 (0%)0/20 (0%)4/20 (20%)
Sham TMS0/17 (0%)0/17 (0%)0/17 (0%)
Most frequent other events
Most frequent other events
EventNetwork-guided TMSSham TMS
Mood changesPsychiatric disorders1/200/17
NeuralgiaNervous system disorders1/200/17
Incidental finding during fMRINeoplasms benign, malignant and unspecified (incl cysts and polyps)1/200/17
HeadacheNervous system disorders1/200/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Network-guided TMSSham TMSTotal
Mean72.6 ± 5.673.3 ± 3.372.9 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)Network-guided TMSSham TMSTotal
Female15823
Male5914
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Network-guided TMSSham TMSTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White181533
More than one race011
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Network-guided TMSSham TMSTotal
Hispanic or Latino101
Not Hispanic or Latino181735
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Network-guided TMSSham TMSTotal
United States201737
08

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jun 2025, 39 months.

Results were first posted in Oct 2026, 1 year 4 months after primary completion.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 39 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2020
First posted
Sep 16, 2020
StartActual
Mar 8, 2022
Primary completionActual
Jun 27, 2025
CompletionActual
Jun 27, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Eligibility
Minimum age 55 Years→60 Years; Maximum age 80 Years→82 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedElderly: age between 5560-8082
Oct 27, 2026
Primary outcomes
1 edited, 1 added, 2 removed
What changed in the outcomes
  • EditedChange in Episodic Memory Task Performance (accuracy and response time)Time frame: Baseline + 2 followup sessions on subsequent days (Day 1, Day 2, Day 3) → Baseline + Follow-up session, at day 3
  • AddedChange in Representational Strength of Episodic MemoriesTime frame: Baseline + Follow-up session, at day 3
  • RemovedChange in neurovascular reactivity, as measured by resting-state fluctuations in activity (RSFA)Time frame: During 3 followup sessions (Day 2, Day 3, Day 4)
  • RemovedChange in structural connectivity, as measured by fractional anisotropy (FA)Time frame: During 3 followup sessions (Day 2, Day 3, Day 4)
Oct 27, 2026
Documents
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Eligibility Minimum age 55 Years→60 Years; Maximum age 80 Years→82 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedElderly: age between 5560-8082
    Primary outcomes 1 edited, 1 added, 2 removed
    What changed in the outcomes
    • EditedChange in Episodic Memory Task Performance (accuracy and response time)Time frame: Baseline + 2 followup sessions on subsequent days (Day 1, Day 2, Day 3) → Baseline + Follow-up session, at day 3
    • AddedChange in Representational Strength of Episodic MemoriesTime frame: Baseline + Follow-up session, at day 3
    • RemovedChange in neurovascular reactivity, as measured by resting-state fluctuations in activity (RSFA)Time frame: During 3 followup sessions (Day 2, Day 3, Day 4)
    • RemovedChange in structural connectivity, as measured by fractional anisotropy (FA)Time frame: During 3 followup sessions (Day 2, Day 3, Day 4)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04549155
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Mar 8, 2022
Primary completion
Jun 27, 2025
Completion
Jun 27, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Study contacts

Andrew Liu, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion